Filing Flows › Iovance Biotherapeutics (IOVA) › Q3 2026
Iovance Biotherapeutics (IOVA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Iovance Biotherapeutics (IOVA) reported revenue of $121M for the third quarter 2026 (Q3 2026), +80% from a year earlier and +22% from the quarter before. Operating margin was -19.7%, net loss $22.3M (18.3% of revenue).
Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%, net loss $22.3M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $121M | +22% | +80% |
| Operating profit | −$24.0M | — | — |
| Net earnings | −$22.3M | — | — |
| Operating cash flow | −$4.5M | — | — |
What changed
Revenue was $121.5M in Q3 2026, up 80% year over year and up 22% from the previous quarter.
Operating costs exceeded revenue by $24.0M, an operating margin of -19.7%. Total costs fell 10% while revenue rose 80%. The fastest-growing cost line was Cost of revenue (+25%). The quarter ended with a net loss of $22.3M, narrower than the previous quarter's $47.3M loss.
Operating cash flow was −$4.5M. Non-cash charges added back $3.8M of depreciation and amortization and $11.8M of share-based compensation. Working capital and other items added $2.2M. Capital expenditures of $4.7M exceeded it, leaving free cash flow of −$9.2M.
Questions
What was Iovance Biotherapeutics' revenue in the third quarter 2026?
Iovance Biotherapeutics (IOVA) reported revenue of $121M for the third quarter 2026 (Q3 2026), +80% from a year earlier and +22% from the quarter before.
Was Iovance Biotherapeutics profitable in the third quarter 2026?
Operating loss was $24.0M (-19.7% of revenue) and net loss $22.3M.